Jeffrey Turner, MD, discusses the discovery of cardiovascular and renal benefits in SGLT2 inhibitors, and Nihar R. Desai, MD, MPH, provides insight into the role of SGLT2 inhibitors in the four ...

Jeffrey Turner, MD, and Nihar R. Desai, MD, MPH, provide insight into the identification of high-risk patients with cardiorenal metabolic syndrome and the impact of case-management resources on ...

Acute cardiorenal (type 1) Acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction Acute decompensated heart failure, acute coronary syndrome Chronic cardiorenal (type ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Chiadi E. Ndumele, ...

Please provide your email address to receive an email when new articles are posted on . The Cover Story this month in Healio/ Nephrology News & Issues focuses on obesity and its relationship to ...

Around 25–33% of patients with acute decompensated heart failure develop worsening kidney function, a condition referred to as acute cardiorenal syndrome (type 1). Diuretics are commonly used to treat ...

Nephrology & Hypertension, Deepak Jasuja, M.D., a nephrologist, collaborates with a team of cardiologists to treat patients ...

A panel of US-based experts in cardiology, nephrology, endocrinology, and primary care has prepared specific recommendations for early identification and intervention in obesity, diabetes, and other ...

Please provide your email address to receive an email when new articles are posted on . The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart ...

DENVER, May 28, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing ...